Clinical Trials
4 trialsNCT05308446 2026-06-03
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04017650 2026-05-22
Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT03803553 2026-05-01
Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer
Massachusetts General Hospital
Phase 3 Recruiting
NCT05217446 2026-04-07
SEAMARK
Pfizer
Phase 2 Active not recruiting